Genmab upgrades 2022 guidance
![Photo: Joost Melis / Genmab / PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article14139217.ece/ALTERNATES/schema-16_9/doc7lex7y1o6y11mhe3x80q.jpg)
Genmab upgrades its full-year guidance for 2022, now projecting annual revenue of DKK 12-13bn (USD 1.64-1.78bn) and operating profit totaling DKK 3.8-5.4bn (USD 521.3–740.8m).
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Genmab and Biontech expand their partnership
For subscribers
Wellington owns almost 5% of Genmab shares
For subscribers